The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Open accessAbstract
Isoprenylcysteine carboxyl methyltransferase (Icmt) methylates the carboxyl-terminal isoprenylcysteine of CAAX proteins (e.g., Ras and Rho proteins). In the case of the Ras proteins, carboxyl methylation is important for targeting of the proteins to the plasma membrane. We hypothesized that a knockout of Icmt would reduce the ability of cells to be transformed by K-Ras. Fibroblasts harboring a floxed Icmt allele and expressing activated K-Ras (K-Ras-Icmt(flx/flx)) were treated with Cre-adenovirus, producing K-Ras-Icmt(Delta/Delta) fibroblasts. Inactivation of Icmt inhibited cell growth and K-Ras-induced oncogenic transformation, both in soft agar assays and in a nude mice model. The inactivation of Icmt did not affect growth factor-stimulated phosphorylation of Erk1/2 or Akt1. However, levels of RhoA were greatly reduced as a consequence of accelerated protein turnover. In addition, there was a large Ras/Erk1/2-dependent increase in p21(Cip1), which was probably a consequence of the reduced levels of RhoA. Deletion of p21(Cip1) restored the ability of K-Ras-Icmt(Delta/Delta) fibroblasts to grow in soft agar. The effect of inactivating Icmt was not limited to the inhibition of K-Ras-induced transformation: inactivation of Icmt blocked transformation by an oncogenic form of B-Raf (V599E). These studies identify Icmt as a potential target for reducing the growth of K-Ras- and B-Raf-induced malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alternative compounds targeting enzymes that modify RAS proteins post-prenylation, ICMT and RCE1, have been tested and show anti-cancer activity in cell and animal models [41,42].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [41]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Inhibition of purified p21 farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 815
Self-citation
Research works printed but not linked: 4
- Bos, 1989, Cancer Res., 49, 4682
- Omer, 2000, Cancer Res., 60, 2680
- Oliff, 1999, Biochim. Biophys. Acta., 1423, C19
- Webber, 1994, Am. J. Pathol., 145, 398
Cited by
Sorted by citations
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K. M., Bar‐Sagi, D., & Philips, M. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 578
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 562
Protein prenylation: unique fats make their mark on biology
Wang, M., & Casey, P. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.11 · Cited by 552
Self-citationKonstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 460
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification
Roberts, P. J., Mitin, N., Keller, P. J., Chenette, E. J., Madigan, J. P., Currin, R. O., Cox, A. D., Wilson, O., Kirschmeier, P., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800882200 · Cited by 362
Post-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Self-citationWright, L. P., & Philips, M. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600004-jlr200 · Cited by 340
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M. B., Young, A. E., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 329
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 292
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242
Young, S. G., Fong, L. G., & Michaelis, S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.r500011-jlr200 · Cited by 218
Self-citationTherapeutic intervention based on protein prenylation and associated modifications
Gelb, M. H., Brunsveld, L., Hrycyna, C. A., Michaelis, S., Tamanoi, F., Voorhis, W. C. V., & Waldmann, H. (2006) · Nature Chemical Biology · doi:10.1038/nchembio818 · Cited by 195
Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178
Self-citationOkada, K., Tanaka, H., Temporin, K., OKAMOTO, M. T., Kuroda, Y., Moritomo, H., Murase, T., & Yoshikawa, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.12.017 · Cited by 172
Sebolt, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0333 · Cited by 168
PostprenylationCAAXProcessing Is Required for Proper Localization of Ras but Not Rho GTPases
Michaelson, D., Ali, W., Chiu, V. K., Bergö, M. O., Silletti, J., Wright, L. P., Young, S. G., & Philips, M. R. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-11-0960 · Cited by 166
Self-citationApproaches of targeting Rho GTPases in cancer drug discovery
Lin, Y., & Zheng, Y. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1058775 · Cited by 140
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Targeting Ras and Rho GTPases as opportunities for cancer therapeutics
Walker, K. M., & Olson, M. F. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.11.001 · Cited by 125
Targeting Isoprenylcysteine Methylation Ameliorates Disease in a Mouse Model of Progeria
Ibrahim, M. X., Sayin, V. I., Akula, M. K., Liu, M., Fong, L. G., Young, S. G., & Bergö, M. O. (2013) · Science · doi:10.1126/science.1238880 · Cited by 128
Self-citationRas acylation, compartmentalization and signaling nanoclusters (Review)
Henis, Y. I., Hancock, J. F., & Prior, I. A. (2009) · Molecular Membrane Biology · doi:10.1080/09687680802649582 · Cited by 130
Wang, M., Tan, W., Zhou, J., Leow, J., Go, M., Lee, H. S., & Casey, P. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801855200 · Cited by 116
Self-citationSjogren, A.-K. M., Andersson, K., Liu, M., Cutts, B. A., Karlsson, C., Wahlstrom, A. M., Dalin, M. G., Weinbaum, C., Casey, P. J., Tarkowski, A., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30868 · Cited by 115
Self-citationYuan, Y., Li, P., Li, J., Zhao, Q., Chang, Y., & He, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01759-7 · Cited by 118
Khan, O. M., Ibrahim, M. X., Jonsson, I., Karlsson, C., Liu, M., Sjogren, A.-K. M., Olofsson, F. J., Brisslert, M., Andersson, S. E. M., Ohlsson, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43758 · Cited by 111
Ntai, I., Fornelli, L., DeHart, C. J., Hutton, J. E., Doubleday, P. F., LeDuc, R. D., van Nispen, A. J., Fellers, R. T., Whiteley, G., Boja, E. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716122115 · Cited by 108
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Lo, H. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357970 · Cited by 97
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development
Mijimolle, N., Velasco, J. A., Dubus, P. R., Guerra, C. E., Weinbaum, C., Casey, P. J., Campuzano, V., & Barbacid, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.004 · Cited by 97
Self-citationOkawa, E. R., Gotoh, T., Manne, J., Igarashi, J., Fujita, T., Silverman, K. A., Xhao, H., Mossé, Y. P., White, P. S., & Brodeur, G. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210675 · Cited by 96
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K., Young, S. G., & Bergö, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 93
Self-citationRAS: Target for Cancer Therapy
Saxena, N., Lahiri, S. S., Hambarde, S., & Tripathi, R. P. (2008) · Cancer Investigation · doi:10.1080/07357900802087275 · Cited by 92
Post-translational Modifications of the Protein Termini
Chen, L., & Kashina, A. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.719590 · Cited by 89
Posttranslational Modifications of RAS ProteinsPreprint
Ahearn, I. M., Zhou, M., & Philips, M. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031484 · Cited by 89
Nishimura, A., & Linder, M. E. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01398-12 · Cited by 87
Densham, R. M., O’Neill, E. E., Munro, J., König, I., Anderson, K. I., Kölch, W., & Olson, M. F. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00116-09 · Cited by 84
Wang, M., Hossain, M. S., Tan, W., Coolman, B., Zhou, J., Liu, S., & Casey, P. J. (2010) · Oncogene · doi:10.1038/onc.2010.247 · Cited by 75
Self-citationJonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 73
Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein
Brummer, T., Martin, P., Herzog, S., Misawa, Y., Daly, R. J., & Reth, M. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209640 · Cited by 70
Tews, B., Felsberg, J., Hartmann, C. J., Kunitz, A., Hahn, M., Toedt, G., Neben, K., Hummerich, L., von Deimling, A., Reifenberger, G., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21901 · Cited by 69
Mohammed, I., Hampton, S. E., Ashall, L., Hildebrandt, E. R., Kutlik, R. A., Manandhar, S. P., Floyd, B. J., Smith, H. E., Dozier, J. K., Distefano, M. D., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.043 · Cited by 66
A general fluorescence-based coupled assay for S-adenosylmethionine-dependent methyltransferases
Wang, C., Leffler, S., Thompson, D. H., & Hrycyna, C. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.170 · Cited by 64
Bracha‐Drori, K., Shichrur, K., Lubetzky, T. C., & Yalovsky, S. (2008) · PLANT PHYSIOLOGY · doi:10.1104/pp.108.120477 · Cited by 63
Lau, H. Y., Ramanujulu, P. M., Guo, D., Yang, T., Wirawan, M., Casey, P. J., Go, M., & Wang, M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29692 · Cited by 63
Self-citationProtein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Tate, E. W., Soday, L., de la Lastra, A. L., Wang, M., & Lin, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00666-x · Cited by 63
Statins and Protein Prenylation in Cancer Cell Biology and Therapy
García‐Ruiz, C., Morales, A., & Fernández-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228715 · Cited by 61
Oncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
Chan, I. T. (2006) · Blood · doi:10.1182/blood-2006-04-015040 · Cited by 65
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
Yang, J., Kulkarni, K. A., Manolaridis, I., Zhang, Z., Dodd, R. B., Mas-Droux, C., & Barford, D. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.020 · Cited by 57
Judd, W. R., Slattum, P. M., Hoang, K. C., Bhoite, L. T., Valppu, L., Alberts, G. L., Brown, B., Roth, B. L., Ostanin, K., Huang, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200249a · Cited by 56
Manu, K. A., Chai, T. F., Teh, J. T., Zhu, W. L., Casey, P. J., & Wang, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0703 · Cited by 55
Self-citationPost-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 54
Khan, O. M., Akula, M. K., Skålén, K., Karlsson, C., Ståhlman, M., Young, S. G., Borén, J., & Bergö, M. O. (2013) · Circulation · doi:10.1161/circulationaha.112.000588 · Cited by 55
Self-citationCourt, H., Amoyel, M., Hackman, M., Lee, K. E., Xu, R., Miller, G., Bar‐Sagi, D., Bach, E. A., Bergö, M. O., & Philips, M. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65764 · Cited by 54
Cushman, I., & Casey, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025296 · Cited by 49
Self-citationMarín‐Ramos, N. I., Balabasquer, M., Ortega-Nogales, F. J., Torrecillas, I. R., Gil-Ordóñez, A., Marcos‐Ramiro, B., Aguilar-Garrido, P., Cushman, I., Romero, A., Medrano, F. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00145 · Cited by 51
p21cip1/waf1 Coordinates Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress
Manu, K. A., Cao, P. H. A., Chai, T. F., Casey, P. J., & Wang, M. (2019) · Cancers · doi:10.3390/cancers11081112 · Cited by 47
Self-citationGarant, K. A., Shmulevitz, M., Pan, L., Daigle, R., Ahn, D.-G., Gujar, S. A., & Lee, P. W. K. (2015) · Oncogene · doi:10.1038/onc.2015.136 · Cited by 47
Anderson, J. L., Frase, H., Michaelis, S., & Hrycyna, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410292200 · Cited by 47
Lau, H. Y., Tang, J., Casey, P. J., & Wang, M. (2017) · Oncogene · doi:10.1038/onc.2016.508 · Cited by 46
Self-citationBlocking Ras inhibition as an antitumor strategy
Marín‐Ramos, N. I., Ortega‐Gutiérrez, S., & López-Rodríguez, M. L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.017 · Cited by 46
Amino Derivatives of Indole As Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase
Go, M., Leow, J. L., Gorla, S. K., Schüller, A., Wang, M., & Casey, P. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002843 · Cited by 45
Self-citationColeman, M. L., Densham, R. M., Croft, D. R., & Olson, M. F. (2005) · Oncogene · doi:10.1038/sj.onc.1209322 · Cited by 44
Efforts to Develop KRAS Inhibitors
Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43
Gentry, L. R., Nishimura, A., Cox, A. D., Martin, T. D., Tsygankov, D., Nishida, M., Elston, T. C., & Der, C. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.656710 · Cited by 45
Okada, K., Tanaka, H., Temporin, K., OKAMOTO, M. T., Kuroda, Y., Moritomo, H., Murase, T., & Yoshikawa, H. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.03.065 · Cited by 42
Bergman, J. A., Hahne, K., Jiao, S., Hrycyna, C. A., & Gibbs, R. A. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200106d · Cited by 41
Peterson, Y. K., Wang, X. S., Casey, P. J., & Tropsha, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013772 · Cited by 41
Self-citationThe Isoprenoid Substrate Specificity of Isoprenylcysteine Carboxylmethyltransferase
Anderson, J. L., Henriksen, B. S., Gibbs, R. A., & Hrycyna, C. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504982200 · Cited by 38
A Role for Rac3 GTPase in the Regulation of Autophagy
Zhu, W., Hossain, M. S., Guo, D. Y., Liu, S., Tong, H., Khakpoor, A., Casey, P. J., & Wang, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.280990 · Cited by 36
Self-citationBenetka, W., Koranda, M., & Eisenhaber, F. (2006) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-006-0534-9 · Cited by 35
Do, M. T., Chai, T. F., Casey, P. J., & Wang, M. (2017) · Oncogene · doi:10.1038/onc.2017.183 · Cited by 36
Self-citationBaron, R., & Casey, P. J. (2004) · BMC Biochemistry · doi:10.1186/1471-2091-5-19 · Cited by 35
Self-citationPrenylation of HDAg and Antiviral Drug Development
Glenn, J. S. (2006) · Springer eBooks · doi:10.1007/3-540-29802-9_7 · Cited by 34
de la Vega, M., Burrows, J. F., McFarlane, C., Govender, U., Scott, C. J., & Johnston, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081448 · Cited by 33
Mattingly, R. R. (2013) · ISRN Oncology · doi:10.1155/2013/536529 · Cited by 33
Teh, J. T., Zhu, W., Ilkayeva, O., Li, Y., Gooding, J. R., Casey, P. J., Summers, S. A., Newgard, C. B., & Wang, M. (2014) · Oncogene · doi:10.1038/onc.2014.260 · Cited by 31
Self-citationWright, L. P., Court, H., Mor, A., Ahearn, I. M., Casey, P. J., & Philips, M. R. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01719-08 · Cited by 31
Self-citationChen, F., Li, X., Zhu, H.-P., & Huang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00280 · Cited by 30
Identification of selectively expressed genes and antigens in CTCL
Hartmann, T. B., Mattern, E., Wiedemann, N., van Doorn, R., Willemze, R., Niikura, T., Hildenbrand, R., Schadendorf, D., & Eichmüller, S. B. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00637.x · Cited by 28
Majmudar, J. D., Hodges, H. B., Hahne, K., Donelson, J. L., Song, J., Shrestha, L., Harrison, M. L., Hrycyna, C. A., & Gibbs, R. A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.087 · Cited by 28
Ramanujulu, P. M., Yang, T., Yap, S.-Q., Wong, F. M., Casey, P. J., Wang, M., & Go, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.007 · Cited by 28
Self-citationKonstantinopoulos, P. A., & Papavassiliou, A. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.005 · Cited by 28
Fighting cancer by disrupting C-terminal methylation of signaling proteins
Clarke, S. G., & Tamanoi, F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421059 · Cited by 28
A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells
Chen, X., Yao, H., Kashif, M., Revêchon, G., Eriksson, M., Hu, J., Wang, T., Liu, Y., Tüksammel, E., Strömblad, S., et al. (2021) · eLife · doi:10.7554/elife.63284 · Cited by 29
Small GTPase patterning: How to stabilise cluster coexistence
Jacobs, B., Molenaar, J., & Deinum, E. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213188 · Cited by 27
Proteomic Analysis of Bovine Brain G Protein γ Subunit Processing Heterogeneity
Cook, L. A., Schey, K. L., Wilcox, M. D., Dingus, J., Ettling, R., Nelson, T., Knapp, D. R., & Hildebrandt, J. D. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500223-mcp200 · Cited by 27
Cushman, I., & Casey, P. J. (2011) · Cell Adhesion & Migration · doi:10.4161/cam.5.1.13196 · Cited by 26
Self-citationPrenylcysteine methylesterase in Arabidopsis thaliana
Deem, A. K., Bultema, R. L., & Crowell, D. N. (2006) · Gene · doi:10.1016/j.gene.2006.05.023 · Cited by 24
Genetic and Pharmacologic Analyses of the Role of Icmt in Ras Membrane Association and Function
Svensson, A. W., Casey, P. J., Young, S. G., & Bergö, M. O. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07013-8 · Cited by 22
Self-citationGriggs, A. M., Hahne, K., & Hrycyna, C. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.061366 · Cited by 22
Baron, R., Peterson, Y. K., Otto, J. C., Rudolph, J., & Casey, P. J. (2006) · Biochemistry · doi:10.1021/bi060344n · Cited by 22
Self-citationIsoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents
Yang, W. S., Yeo, S., Yang, S., Kim, K., Yoo, B. C., & Cho, J. Y. (2017) · Amino Acids · doi:10.1007/s00726-017-2454-x · Cited by 20
Pan, Q., Liu, R., Banu, H., Ma, L., & Li, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.048 · Cited by 20
Pan, Q., Xu, J., & Ma, L. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12479 · Cited by 20
Ullah, N., & Arafeh, K. M. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.10.103 · Cited by 20
Metadata
- Authors
- Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G.
- Affiliations
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- Duke Medical Center (US)
- San Francisco General Hospital (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 539-550
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC338259
- OpenAlex
- W2112532834
- Cited by
- 180
- References
- 46
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 1 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 9 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 13 · 2012: 3
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tobacco-Related Disease Research Program
- Swedish Foundation for International Cooperation in Research and Higher Education
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL-41633, P01HL041633)
- National Cancer Institute (R01CA099506)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR050200)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- isoprenylcysteine carboxyl methyltransferase, IcmT, oncogenic KRAS, oncogenic transformation, RhoA, p21, protein turnover, cell growth inhibition, targeted cancer therapy
- MeSH terms
- Alleles, Animals, Cell Division, Cell Line, Cell Transformation, Neoplastic, Fibroblasts, Humans, Mice, Nude, Phenotype, Protein Methyltransferases, Proto-Oncogene Proteins, Genes, ras, Cyclins, Protein Serine-Threonine Kinases, ras Proteins, Proto-Oncogene Proteins c-raf, rho GTP-Binding Proteins, Mitogen-Activated Protein Kinases, Cyclin-Dependent Kinase Inhibitor p21, Proto-Oncogene Proteins c-akt, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review